Back to Search
Start Over
Immune checkpoint inhibitors and cardiovascular toxicity.
- Source :
-
Lancet Oncology . Sep2018, Vol. 19 Issue 9, pe447-e458. 12p. - Publication Year :
- 2018
-
Abstract
- Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-mediated immune responses against cancer cells. Immune checkpoint inhibitors have shown important benefits in phase 3 trials, and several agents have been approved for specific malignancies. Although adverse events from immune checkpoint inhibitors are a common occurrence, cardiotoxic effects are uncommon, but are often serious complications with a relatively high mortality. Most cardiotoxic effects appear to be inflammatory in nature. Clinical assessment of a combination of biomarkers, electrocardiography, cardiac imaging, and endomyocardial biopsy can be used to confirm a possible diagnosis. In this Review, we discuss the epidemiology of immune checkpoint inhibitor-mediated cardiotoxic effects, as well as their clinical presentation, subtypes, risk factors, pathophysiology, and clinical management, including the introduction of a new surveillance strategy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14702045
- Volume :
- 19
- Issue :
- 9
- Database :
- Academic Search Index
- Journal :
- Lancet Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 131650642
- Full Text :
- https://doi.org/10.1016/S1470-2045(18)30457-1